"Patient"

Data from a study of a cancer vaccine combined with a PD-1 immune checkpoint inhibitor has recently been released, and the treatment has increased the survival of patients with advanced colorectal cancer by more than three times, with some patients surviving for more than 22 months so far.

The continuous high temperature and hot weather in summer can not be ignored for people with cardiovascular diseases. Once they relax their vigilance, heart failure is very likely to occur, and heart failure is the end stage of various heart diseases, known as the stumbling block of life, which seriously endangers life and health.

Recently, the European Commission has approved cemiplimab-rwlc (Libtayo), manufactured by US-based Regeneron, as a monotherapy for the treatment of adult patients with recurrent or metastatic cervical cancer whose disease has progressed during or after platinum-containing chemotherapy. The results of the trial showed that this therapy significantly improved patient survival and had a good safety profile.

With more and more new cutting-edge drugs emerging, the standard treatment paradigm for breast cancer is now rapidly changing, and the future is looking brighter for patients.

A dendritic cell vaccine has shown excellent results in the treatment of glioblastoma, significantly extending the survival of patients with a good safety profile, according to new data from a global clinical trial. To date, patients who have benefited for the longest time have survived for more than eight years.

We all know that we need to pay attention to our diet after suffering from a disease, because improper diet will affect the recovery of the disease and the health of the patient.

Researchers at the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai have now identified a new treatment that promises to help cancer patients with bone marrow transplants manage side effects better than current standard therapies, making the treatment more effective and safer.

Scientists from MIT designed a microfluidic device to capture and count circulating plasma cells in small samples of blood. This technique can only be carried out through routine blood drawing, which is expected to reduce the pain of patients' myeloma testing.

For patients with relapsed and refractory multiple myeloma, the CAR-T cell therapy Ide-cel resulted in a two-fold increase in the average length of time that patients' tumours did not progress compared to standard treatment, with 71% of patients experiencing substantial tumour regression and 39% experiencing complete tumour disappearance.

According to data from an ongoing Phase I/Ib clinical trial (NCT04374877), an innovative IL-27 inhibitor called SRF388 has shown promising results in the treatment of locally advanced or advanced non-small cell lung cancer (NSCLC), which undoubtedly brings new hope for the treatment of lung cancer patients in general!